Gastroesophageal Reflux Disease (GERD)
Therapeutics Market Competitive Landscape
Report to 2025
The Gastroesophageal Reflux Disease (GERD) therapeutics Market report provides in-depth analysis and insights into
developments impacting businesses and enterprises on global and regional level. The report covers the global
Gastroesophageal Reflux Disease (GERD) therapeutics Market performance in terms of revenue contribution from
various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing
revenue growth of the global Gastroesophageal Reflux Disease (GERD) therapeutics market. This report studies the
global Gastroesophageal Reflux Disease (GERD) therapeutics Market size, industry status and forecast, competition
landscape and growth opportunity. This research report categorizes the global Gastroesophageal Reflux Disease (GERD)
therapeutics Market by companies, region, type and end-use industry.
The global Gastroesophageal Reflux Disease (GERD) therapeutics market size was valued at USD 5.66 billion in 2016 and
by is estimated to be USD 4.34 billion by 2025, it is anticipated to observe a decrease in its revenue at a negative CAGR
of -2.9%. Expiration of patented blockbuster drugs, which are indicated for the management of disorders of acid reflux is
major restraining factors for this market.
With strong clinical pipelines and patent litigations, the market continues to experience significant changes. Proton
pump inhibitors (PPI) and antagonists of histamine H2 receptor have the importance in current scenario of the market.
Upon loss of patent protection of formerly leading branded drugs, generic molecules with low-price can ingest the sales
of the branded ones up to 90%. Rising number of companies being exposed to price scrutiny associated with shift in the
focus of government on the promotion of consumer convenience will stimulate further reduction of drug prices.
Although market turnover is affecte